Heart failure in diabetes: From an increased risk to a treatment target

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Heart failure (HF) is one of the most common comorbidities of type 2 diabetes mellitus (T2DM) and poor glycaemic control can worsen the HF outcomes and increase the risk of hospitalisations. With the entry of several antihyperglycaemic agents for the management of T2DM over the last decade, there has been an increasing concern regarding the cardiovascular (CV) safety profile of these agents. In view of this, FDA mandated the demonstration of cardiovascular risk-benefit profile of these agents through specifically designed CV outcome trials. Although we have several findings from these trials, none of them included HF as a primary endpoint indicating the need of trials focusing on HF. Here, we briefly discuss the results of the CV outcome trials in the context of HF.

About the authors

Standl Eberhard

Munich Diabetes Research Group e.V. at Helmholtz Centre
 

Author for correspondence.
Email: eberhard.standl@lrz.uni-muenchen.de

MD, PhD

Germany, Ingolstaedter Land-St 1 85764 Neuherberg, Germany.

Supplementary files

There are no supplementary files to display.

Statistics

Views

Abstract: 22

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) Eberhard S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies